Source: Health Products Regulatory Authority (ZA) Revision Year: 2023 Publisher: Pharmacorp (Pty) Ltd, 29 Victoria Link, Route 21 Corporate Park, Irene, 0178, Pretoria
Pharmacotherapeutic group: Mefenamic acid, M01AG01
Pharmacological classification: A 2.7 Antipyretic and anti-inflammatory analgesic
Mefenamic acid is a non-steroidal anti-inflammatory medicine (NSAIDs) with antipyretic and analgesic properties. It has central as well as peripheral analgesic actions. Mefenamic acid inhibits cyclo-oxygenase non selectively and thereby antagonises certain effects of prostaglandins in analgesia.
Mefenamic acid is well absorbed from the gastrointestinal tract. Peak plasma concentrations occur in about 2 to 4 hours, with a half-life of 2 to 4 hours. Plasma levels are proportional to dose. Accumulation does not occur following repeated doses.
Mefenamic acid is extensively bound to plasma proteins. Over 50% of the dose may be recovered in the urine as unchanged substance or as conjugated metabolites.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.